1,300 Dead in Outbreak; Cyclospora Response ‘Mismanaged’? GLP-1 Access in Medicaid
Tuesday, July 28 – (MedPage Today) — Note that some links may require registration or subscription.
More healthcare workers in Congo went on strike as confirmed Ebola cases in the nation approached 3,000, including 1,309 deaths. (AP)
Florida reported the state…
GLP-1s Like Ozempic, Wegovy Can Help Maintain Lower Calorie Intake for Over 1 Year
Sunday, July 26 – Recent research has found that GLP-1s, like Ozempic and Wegovy, can help you maintain a lower calorie intake for more than a year. Image Credit: Jon Challicom/Getty
A new study found that people taking semaglutide (Ozempic and Wegovy) maintained a significantly lower calorie intake after 60 weeks on the medication.
Participants taking semaglutide consistently consumed 24% to 30% fewer calories than those receiving a placebo throughout the study.
The findings suggest semaglutide may continue supporting weight loss even after differences in hunger and food cravings begin to fade.
Millions of people are losing weight using GLP-1s. How do the drugs affect their love lives?
Sunday, July 26 – Prescribing doctors often warn of the medications’ potential side-effects – but unexpected impacts on romantic relationships are less understoodFor Jennifer, obesity was the obvious culprit for most of her problems.The litigation attorney told herself it was the reason why she wasn’t being invited to parties, and why she and her husband struggled with physical intimacy in their otherwise “solid” marriage.Sign up for a weekly email featuring our best reads Continue reading…
GLP-1s and Alcohol Use Disorder; No Luck With Gonorrhea Vaccine
Sunday, July 26 – (MedPage Today) — TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of Texas Tech Health El Paso, look at the top medical…
Study Links GLP-1s to Lower Risk of Fragility Fractures in Diabetes Patients
Sunday, July 26 – (MedPage Today) — Starting a GLP-1 receptor agonist for type 2 diabetes was associated with a lower risk of fragility fractures in adults 50 and older, including hip and vertebral fractures, according to a large target trial emulation study….
Oral GLP-1 drugs may quiet the brain’s food craving circuit
Sunday, July 26 – Newer oral drugs related to semaglutide medications such as Ozempic reduced pleasure-driven eating in mice by quieting a deep brain reward circuit. The finding could open new avenues for understanding food cravings and potentially treating substance use disorder.
‘Ozempic face’ and hair loss: what evidence is there for weight-loss drug side-effects?
Sunday, July 26 – Research into GLP-1 medications is not always robust but complaints such as digestive problems are well knownWeight loss jabs such as Wegovy and Mounjaro have boomed in popularity, and so have reports of myriad side-effects. This week researchers have suggested GLP-1 medications could be associated with hair loss.It can be hard to keep tabs on which of these unintentional outcomes have been the subject of expert scrutiny and which remain little more than hearsay. We take a look at some of the most talked about side-effects and explore which have been studied – and which remain unproven. Continue reading…
“It’s Like A Switch Has Been Shut Off In My Brain”: People Are Sharing How GLP-1s Like Ozempic And Mounjaro Have Really Changed Their Lives
Saturday, July 25 – “This medicine erased years and years of self-hate, cured my eating disorder, reduced the pain in my body and improved my intracranial hypertension.”View Entire Post ›
What Are Compounders Commonly Adding to GLP-1 Drugs?
Saturday, July 25 – (MedPage Today) — You passed medical training, now see if you can pass our weekly quiz
Novo Asks NJ Judge To Stop Lilly’s ‘Deceptive’ GLP-1 Ads
Saturday, July 25 – Novo Nordisk Inc. asked a New Jersey federal court Friday to block rival Eli Lilly & Co. from running ads allegedly comparing their respective GLP-1 drugs using “outdated” clinical trials and “false superiority messages,” arguing the ads are damaging its reputation and misleading consumers.